Business Description
C4 Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US12529R1077
Share Class Description:
CCCC: Ordinary SharesTotal Employee Number:
104Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.03 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.58 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.38 | |||||
Beneish M-Score | -2.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12 | |||||
3-Year EBITDA Growth Rate | 21.4 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 19.3 | |||||
3-Year Book Growth Rate | -23.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -20.58 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.53 | |||||
9-Day RSI | 45.19 | |||||
14-Day RSI | 49.66 | |||||
3-1 Month Momentum % | 52.66 | |||||
6-1 Month Momentum % | 80.84 | |||||
12-1 Month Momentum % | 94.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9 | |||||
Quick Ratio | 9 | |||||
Cash Ratio | 8.65 | |||||
Days Sales Outstanding | 46.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.6 | |||||
Shareholder Yield % | 1.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -295.78 | |||||
Net Margin % | -297.76 | |||||
EBITDA Margin % | -290.3 | |||||
FCF Margin % | -273.71 | |||||
OCF Margin % | -273.52 | |||||
ROE % | -51.16 | |||||
ROA % | -33.07 | |||||
ROIC % | -93.28 | |||||
3-Year ROIIC % | -53.34 | |||||
ROC (Joel Greenblatt) % | -200.54 | |||||
ROCE % | -37.14 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 10.42 | |||||
PB Ratio | 1.8 | |||||
Price-to-Tangible-Book | 1.8 | |||||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -2.68 | |||||
EV-to-Revenue | 7.79 | |||||
EV-to-Forward-Revenue | 10 | |||||
EV-to-FCF | -2.85 | |||||
Price-to-GF-Value | 2.13 | |||||
| Price-to-Net-Current-Asset-Value | 2.8 | |||||
| Price-to-Net-Cash | 2.99 | |||||
Earnings Yield (Greenblatt) % | -38.02 | |||||
FCF Yield % | -21.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CCCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
C4 Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.861 | ||
| EPS (TTM) ($) | -1.19 | ||
| Beta | 4.2806 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.73 | ||
| Volatility % | 86.4 | ||
| 14-Day RSI | 49.66 | ||
| 14-Day ATR ($) | 0.392161 | ||
| 20-Day SMA ($) | 4.172 | ||
| 12-1 Month Momentum % | 94.47 | ||
| 52-Week Range ($) | 1.6901 - 5.17 | ||
| Shares Outstanding (Mil) | 110.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
C4 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
C4 Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-06-24 08:30 | 4.22 (+4.98%) | ||
| Guidance call for 2026 | 2026-06-04 09:20 | 3.96 (-7.91%) | ||
| TD Cowen\'s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 14:30 | 3.56 (-0.28%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.17 (+7.46%) | ||
| Barclays 28 Annual Global Healthcare Conference | 2026-03-10 08:00 | 3.59 (+21.08%) | ||
| TD Cowen 46 Annual Healthcare Conference | 2026-03-03 11:50 | 3.17 (+21.46%) | ||
| Annual report for 2025 | 2026-02-26 | 2.77 (+14.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 2.77 (+14.94%) |
Show
Entries
C4 Therapeutics Inc Frequently Asked Questions
What is C4 Therapeutics Inc(CCCC)'s stock price today?
The current price of CCCC is $4.06. The 52 week high of CCCC is $5.17 and 52 week low is $1.69.
When is next earnings date of C4 Therapeutics Inc(CCCC)?
The next earnings date of C4 Therapeutics Inc(CCCC) is 2026-08-07 Est..
Does C4 Therapeutics Inc(CCCC) pay dividends? If so, how much?
C4 Therapeutics Inc(CCCC) does not pay dividend.
Guru Commentaries on NAS:CCCC
No articles.
Press Release
Articles on C4 Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers